Revolution Medicines Valuation
| RVMD Stock | USD 101.83 0.91 0.89% |
At this time, the company appears to be fairly valued. Revolution Medicines holds a recent Real Value of $102.74 per share. The prevailing price of the company is $101.83. Our model determines the value of Revolution Medicines from analyzing the company fundamentals such as Shares Owned By Institutions of 98.13 %, shares outstanding of 193.32 M, and Return On Equity of -0.61 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Revolution Medicines' valuation include:
Price Book 11.6665 | Enterprise Value | Enterprise Value Ebitda (9.71) | Price Sales 9 K | Enterprise Value Revenue 8.4 K |
Fairly Valued
Today
Please note that Revolution Medicines' price fluctuation is very steady at this time. Calculation of the real value of Revolution Medicines is based on 3 months time horizon. Increasing Revolution Medicines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Revolution stock is determined by what a typical buyer is willing to pay for full or partial control of Revolution Medicines. Since Revolution Medicines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Revolution Stock. However, Revolution Medicines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 101.83 | Real 102.74 | Target 121.94 | Hype 101.82 | Naive 120.96 |
The real value of Revolution Stock, also known as its intrinsic value, is the underlying worth of Revolution Medicines Company, which is reflected in its stock price. It is based on Revolution Medicines' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Revolution Medicines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Revolution Medicines helps investors to forecast how Revolution stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Revolution Medicines more accurately as focusing exclusively on Revolution Medicines' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Revolution Medicines' intrinsic value based on its ongoing forecasts of Revolution Medicines' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Revolution Medicines' closest peers. If more than one evaluation category is relevant for Revolution Medicines we suggest using both methods to arrive at a better estimate.
Revolution Medicines Cash |
|
Revolution Medicines Total Value Analysis
Revolution Medicines is at this time expected to have valuation of 16.85 B with market capitalization of 19.86 B, debt of 135.84 M, and cash on hands of 461.43 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Revolution Medicines fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.85 B | 19.86 B | 135.84 M | 461.43 M |
Revolution Medicines Asset Utilization
One of the ways to look at asset utilization of Revolution is to check how much profit was generated for every dollar of assets it reports. Revolution Medicines holds a negative application of assets of -0.32 pct., losing $0.003229 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Revolution Medicines shows how discouraging it operates for each dollar spent on its assets.Revolution Medicines Profitability Analysis
Based on Revolution Medicines' profitability indicators, Revolution Medicines may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Revolution Medicines' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-09-30 | Previous Quarter -247.8 M | Current Value -305.2 M | Quarterly Volatility 78 M |
For Revolution Medicines profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Revolution Medicines to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Revolution Medicines utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Revolution Medicines's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Revolution Medicines over time as well as its relative position and ranking within its peers.
Revolution Medicines Earnings per Share Projection vs Actual
The next projected EPS of Revolution Medicines is estimated to be -1.632525 with future projections ranging from a low of -1.9325 to a high of -1.28. Revolution Medicines' most recent 12-month trailing earnings per share (EPS TTM) is at -5.19. Please be aware that the consensus of earnings estimates for Revolution Medicines is based on EPS before non-recurring items and includes expenses related to employee stock options.Revolution Medicines Earnings Estimation Breakdown
The calculation of Revolution Medicines' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Revolution Medicines is estimated to be -1.632525 with the future projection ranging from a low of -1.9325 to a high of -1.28. Please be aware that this consensus of annual earnings estimates for Revolution Medicines is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.93 Lowest | Expected EPS | -1.28 Highest |
Revolution Medicines Earnings Projection Consensus
Suppose the current estimates of Revolution Medicines' value are higher than the current market price of the Revolution Medicines stock. In this case, investors may conclude that Revolution Medicines is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Revolution Medicines' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 19 | 70.93% | 0.0 | -1.632525 | -5.19 |
Revolution Medicines Ownership Allocation
The majority of Revolution Medicines outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Revolution Medicines to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Revolution Medicines. Please pay attention to any change in the institutional holdings of Revolution Medicines as this could imply that something significant has changed or is about to change at the company.Revolution Medicines Profitability Analysis
Net Loss for the year was (600.09 M) with loss before overhead, payroll, taxes, and interest of (880.48 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Revolution Medicines' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Revolution Medicines and how it compares across the competition.
About Revolution Medicines Valuation
The stock valuation mechanism determines Revolution Medicines' current worth on a weekly basis. Our valuation model uses a comparative analysis of Revolution Medicines. We calculate exposure to Revolution Medicines's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Revolution Medicines's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -533 M | -506.4 M | |
| Pretax Profit Margin | (43.69) | (41.50) | |
| Operating Profit Margin | (48.38) | (45.96) | |
| Net Loss | (43.34) | (41.17) |
Revolution Medicines Current Valuation Indicators
Valuation refers to the process of determining the present value of Revolution Medicines and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Revolution we look at many different elements of the entity such as Revolution's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Revolution Medicines, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Revolution Medicines' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Revolution Medicines' worth.Complementary Tools for Revolution Stock analysis
When running Revolution Medicines' price analysis, check to measure Revolution Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revolution Medicines is operating at the current time. Most of Revolution Medicines' value examination focuses on studying past and present price action to predict the probability of Revolution Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revolution Medicines' price. Additionally, you may evaluate how the addition of Revolution Medicines to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |